{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:13:05Z","timestamp":1791573185824,"version":"4.3.4"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitor (ICI) is one of the most important tumor treatment methods. Although the therapeutic efficiency of immune checkpoint inhibitor mono-therapy is limited, the combination of chemotherapy plus immune checkpoint inhibitors has shown great advantages in cancer treatment. This is mainly due to the fact that tumor reactive T cells could fully provide their anti-tumor function as chemotherapy could not only cause immunogenic cell death to increase antigen presentation, but also improve the immunosuppressive tumor micro-environment to synergize with immune checkpoint inhibitors. However, traditional chemotherapy still has shortcomings such as insufficient drug concentration in tumor region, short drug duration, drug resistance, major adverse events, etc, which might lead to the failure of the therapy. Nano chemotherapeutic drugs, which refer to chemotherapeutic drugs loaded in nano-based drug delivery system, could overcome the above shortcomings of traditional chemotherapeutic drugs to further improve the therapeutic effect of immune checkpoint inhibitors on tumors. Therefore, the scheme of nano chemotherapeutic drugs combined with immune checkpoint inhibitors might lead to improved outcome of cancer patients compared with the scheme of traditional chemotherapy combined with immune checkpoint inhibitors.<\/jats:p>","DOI":"10.3389\/fimmu.2022.963533","type":"journal-article","created":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T04:48:16Z","timestamp":1660020496000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?"],"prefix":"10.3389","volume":"13","author":[{"given":"Xinye","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: Clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu Rev Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2018.1480942","article-title":"Nivolumab for the treatment of colorectal cancer","volume":"18","author":"Smith","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S135157","article-title":"PD1\/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer","volume":"11","author":"Stenehjem","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.002","article-title":"First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer()","volume":"33","author":"Niu","year":"2022","journal-title":"Ann Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: A therapeutic challenge for immunotherapy","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.27782","article-title":"CD8(+) cytotoxic T lymphocytes in cancer immunotherapy: A review","volume":"234","author":"Farhood","year":"2019","journal-title":"J Cell Physiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.117145","article-title":"Hypoxia induces core-to-edge transition of progressive tumoral cells: A critical review on differential yet corroborative roles for HIF-1alpha and HIF-2alpha","volume":"242","author":"Mortezaee","year":"2020","journal-title":"Life Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.117049","article-title":"Stromal reprogramming: A target for tumor therapy","volume":"239","author":"Najafi","year":"2019","journal-title":"Life Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2018-0111","article-title":"Enhancing tumor T cell infiltration to enable cancer immunotherapy","volume":"11","author":"Zhang","year":"2019","journal-title":"Immunotherapy"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01832","article-title":"A phase ib study of the combination of personalized autologous dendritic cell vaccine, aspirin, and standard of care adjuvant chemotherapy followed by nivolumab for resected pancreatic adenocarcinoma-a proof of antigen discovery feasibility in three patients","volume":"10","author":"Bassani-Sternberg","year":"2019","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-Small-Cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1703449","article-title":"Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology","volume":"9","author":"Vanmeerbeek","year":"2020","journal-title":"Oncoimmunology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2009.1","article-title":"Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death","volume":"28","author":"Panaretakis","year":"2009","journal-title":"EMBO J"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1721810","article-title":"PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models","volume":"9","author":"Yamazaki","year":"2020","journal-title":"Oncoimmunology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-014-0719-x","article-title":"The key role of calreticulin in immunomodulation induced by chemotherapeutic agents","volume":"20","author":"Yamamura","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-Derived Suppressor Cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201444879","article-title":"Human regulatory T cells lack the cyclophosphamide-extruding transporter ABCB1 and are more susceptible to cyclophosphamide-induced apoptosis","volume":"44","author":"Dimeloe","year":"2014","journal-title":"Eur J Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-3480","article-title":"Paclitaxel reduces tumor growth by reprogramming tumor-associated macrophages to an M1 profile in a TLR4-dependent manner","volume":"78","author":"Wanderley","year":"2018","journal-title":"Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-1265","article-title":"CCL2\/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy","volume":"74","author":"Ma","year":"2014","journal-title":"Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0433","article-title":"The folate pathway inhibitor pemetrexed pleiotropically enhances effects of cancer immunotherapy","volume":"25","author":"Schaer","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188386","article-title":"Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types","volume":"1874","author":"van den Ende","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3109\/10717541003762854","article-title":"Polymeric drug delivery systems for localized cancer chemotherapy","volume":"17","author":"De Souza","year":"2010","journal-title":"Drug Deliv"},{"key":"B31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ctrv.2017.04.008","article-title":"Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer","volume":"57","author":"Galletti","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00120-021-01569-7","article-title":"Management of chemotherapy side effects and their long-term sequelae","volume":"60","author":"Zraik","year":"2021","journal-title":"Urologe A."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.7.2221.2221","article-title":"Lymphocyte depletion during treatment with intensive chemotherapy for cancer","volume":"84","author":"Mackall","year":"1994","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0669-x","article-title":"Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer","volume":"18","author":"Verma","year":"2016","journal-title":"Breast Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000408","article-title":"Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors","volume":"29","author":"Ghosh","year":"2017","journal-title":"Curr Opin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2038-3","article-title":"Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer","volume":"66","author":"Wesolowski","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"B37","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.emc.2013.09.002","article-title":"An approach to chemotherapy-associated toxicity","volume":"32","author":"Livshits","year":"2014","journal-title":"Emerg Med Clin North Am"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.2967\/jnmt.121.262151","article-title":"Immune checkpoint inhibitor-related adverse effects and (18)F-FDG PET\/CT findings","volume":"49","author":"Schierz","year":"2021","journal-title":"J Nucl Med Technol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216664203","article-title":"Paclitaxel pre-medication: A comparison of two steroid pre-medication protocols","volume":"23","author":"Yenilmez","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2020.101681","article-title":"Immunosuppression in liver transplant","author":"Di Maira","year":"2020","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil(R)\u2013the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J Control Release"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2021.1920248","article-title":"egylated liposomal doxorubicin as first line treatment in aids-related Kaposi's sarcoma: a real-life study","volume":"33","author":"Dalu","year":"2021","journal-title":"J Chemother"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.5.1444","article-title":"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer","volume":"19","author":"Batist","year":"2001","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.7314\/apjcp.2013.14.4.2591","article-title":"Clinical comparison between paclitaxel liposome (Lipusu(R)) and paclitaxel for treatment of patients with metastatic gastric cancer","volume":"14","author":"Xu","year":"2013","journal-title":"Asian Pac J Cancer Prev"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/biom9120789","article-title":"Paclitaxel's mechanistic and clinical effects on breast cancer","volume":"9","author":"Abu Samaan","year":"2019","journal-title":"Biomolecules"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr300","article-title":"Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis","volume":"23","author":"Fasol","year":"2012","journal-title":"Ann Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24359","article-title":"Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non-Hodgkin lymphoma: report of the pivotal phase 2 study","volume":"115","author":"Rodriguez","year":"2009","journal-title":"Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics9020012","article-title":"Liposomal formulations in clinical use: An updated review","volume":"9","author":"Bulbake","year":"2017","journal-title":"Pharmaceutics"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2010.538678","article-title":"Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo","volume":"7","author":"Dicko","year":"2010","journal-title":"Expert Opin Drug Delivery"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2021","article-title":"Phase 2 non-randomised trial of secondary cytoreduction and hyperthermic intraperitoneal chemotherapy in recurrent platinum-sensitive ovarian cancer","volume":"15","author":"Raj","year":"2021","journal-title":"Ecancermedicalscience"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1572-5","article-title":"Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer","volume":"68","author":"Stathopoulos","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S127840","article-title":"nab-Paclitaxel for the treatment of pancreatic cancer","volume":"9","author":"Kim","year":"2017","journal-title":"Cancer Manag Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14105","article-title":"Nab-paclitaxel monotherapy for relapsed small cell lung cancer: Retrospective analysis and review","volume":"40","author":"Nakao","year":"2020","journal-title":"Anticancer Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-017-0066-5","article-title":"Nab-paclitaxel for the treatment of breast cancer: an update across treatment settings","volume":"6","author":"Brufsky","year":"2017","journal-title":"Exp Hematol Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2020.113642","article-title":"Analytical characterization of liposomes and other lipid nanoparticles for drug delivery","volume":"192","author":"Fan","year":"2021","journal-title":"J Pharm BioMed Anal"},{"key":"B57","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: from concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv Drug Delivery Rev"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O'Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01336-6","article-title":"Liposomal irinotecan: A review in metastatic pancreatic adenocarcinoma","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.618206","article-title":"Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus lenvatinib for advanced hepatocellular carcinoma","volume":"11","author":"Mei","year":"2021","journal-title":"Front Oncol"},{"key":"B61","article-title":"Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes","volume":"54","author":"Gabizon","year":"1994","journal-title":"Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41563-020-0755-z","article-title":"The dose threshold for nanoparticle tumour delivery","volume":"19","author":"Ouyang","year":"2020","journal-title":"Nat Mater"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-021-00897-1","article-title":"Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer","volume":"16","author":"Li","year":"2021","journal-title":"Nat Nanotechnol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030281","article-title":"Liposomal irinotecan for treatment of colorectal cancer in a preclinical model","volume":"11","author":"Huang","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.120117","article-title":"Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization","volume":"593","author":"Makwana","year":"2021","journal-title":"Int J Pharm"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S13836","article-title":"Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval","volume":"4","author":"Yamamoto","year":"2011","journal-title":"Onco Targets Ther"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133569","article-title":"Efficacy and cardiotoxicity of liposomal doxorubicin-based chemotherapy in advanced breast cancer: A meta-analysis of ten randomized controlled trials","volume":"10","author":"Xing","year":"2015","journal-title":"PloS One"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1186\/s12885-021-09050-6","article-title":"Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: A real-world study","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0929","article-title":"Motixafortide and pembrolizumab combined to nanoliposomal irinotecan, fluorouracil, and folinic acid in metastatic pancreatic cancer: The COMBAT\/KEYNOTE-202 trial","volume":"27","author":"Bockorny","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.07.028","article-title":"Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial","volume":"159","author":"Lee","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17849","article-title":"Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed\/refractory classical Hodgkin lymphoma","volume":"196","author":"Zhang","year":"2022","journal-title":"Br J Haematol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12967-020-02424-7","article-title":"ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer","volume":"18","author":"Kyte","year":"2020","journal-title":"J Transl Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"eaao1736","DOI":"10.1126\/sciadv.aao1736","article-title":"Elimination of established tumors with nanodisc-based combination chemoimmunotherapy","volume":"4","author":"Kuai","year":"2018","journal-title":"Sci Adv"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2021.08.013","article-title":"Cisplatin nanoparticles possess stronger anti-tumor synergy with PD1\/PD-L1 inhibitors than the parental drug","volume":"135","author":"Shen","year":"2021","journal-title":"Acta Biomater"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2020.12.010","article-title":"The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment","volume":"6","author":"Yang","year":"2021","journal-title":"Bioact Mater"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1515\/dmpt-2018-0032","article-title":"Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles","volume":"34","author":"Alavi","year":"2019","journal-title":"Drug Metab Pers Ther"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3390\/molecules25235672","article-title":"Recent progress in bioconjugation strategies for liposome-mediated drug delivery","volume":"25","author":"Almeida","year":"2020","journal-title":"Molecules"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.963533\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T04:48:20Z","timestamp":1660020500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.963533\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,9]]},"references-count":78,"alternative-id":["10.3389\/fimmu.2022.963533"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.963533","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,9]]},"article-number":"963533"}}